Review article · 2016
EditorialPublished 2011
BRAF Mutations and their Implications in Molecular Targeting Therapies for Gastrointestinal Cancers
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The epidermal growth factor receptor (EGFR) has become an important therapeutic target in gastrointestinal cancers, especially in colorectal cancer. Stimulation of the EGFR activates at least five intracellular signal cascades such as RAS/RAF/MEK(mitogen-activated ERK activating kinase)/ERK(extracellular signal-regulated kinase), PI3K (phosphatidylinositol 3-kinase) /PTEN (phosphatase and tensin homolog)/AKT(v-akt murine thymoma viral oncogene homolog), STAT (signal transducer and activator of transcription), pospholipase C, and SRC/FAK(focal adhesion kinase). These either phosphorylate their target proteins in the cytoplasm or transmit signals from growth factor receptor to the nucleus, thereby initiating subsequent expression of genes that regulate cell proliferation, differentiation, angiogenesis, and survival [1] Recently, monoclonal antibodies have been developed to target EGFR and to inhibit subsequent cellular responses. They include anti-EGFR antibodies such as cetuximab (a chimeric monoclonal immunoglobulin G1 antibody), panitumumab (a fully human monoclonal immunoglobulin G2 antibody), and trastuzumab (a monoclonal antibody against human epidermal growth factor receptor-2 (HER2) as well as inhibitors of tyrosine kinase (TK) domain of EGFR or subsequent molecules such as gefitinib, erlotinib (both inhibitors of EGFR-TK), lapatinib (a dual inhibitor of HER2-TK and EGFR-TK), sunitinib (an inhibitor of the TK of various kinds of proteins), and sorafenib (an inhibitor of RAF, a downstream molecular of RAS). Among these, cetuximab, panitumumab, and trastuzumab have received the most intensive focus of research, and their efficacy has been clearly demonstrated -especially in gastric and colorectal cancer. However, it is also a fact that this efficacy is sometimes modest as objective response rates comprise at best 50% by adding trastuzumab to chemotherapy -even among HER-2 positive gastric cancer patients [2], or between 8 and 11% by cetuximab [3,4] or pamitumumab [5,6] monotherapy in colorectal cancer patients. The efficacy is thus presumed to be restricted to a certain segment of patients. Therefore, identification of predictive markers of response and resistance in performing the EGFR targeting therapies is urgently needed to stratify those patients benefiting most from them. This in turn obviate unnecessary or futile treatment and reduce health care costs, ultimately allowing treatment to be individualized.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Article · 27 Jul 2024
Targeting FGFR2 and NOTCH1 Molecular Interactions: Implications for Novel Drug Development in Cancer Therapy
Conference abstract · 15 Sep 2018
Comparing BRAF mutation status in corresponding primary and metastatic cutaneous melanomas: Implications on optimized targeted therapy
Brief report · 30 Oct 2024
Genetic Landscapes of Cancer Mapping Mutations for Targeted Therapies
Mini review · 31 Aug 2023
Exploring the Role of Glycolysis in Cancer Metabolism: Implications for Targeted Therapies
More from this journal
The newest in Journal of Pharmacogenomics & Pharmacoproteomics.
Article · 31 Dec 2025
Molecular Phenotyping: Integrated Biological Profiles for Understanding Cellular Function and Disease
Article · 31 Dec 2025
Genetic Determinants of Individual Drug Response
Article · 31 Dec 2025
Genetic Variation in Drug Metabolism, Transport, and Treatment Response
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmacogenomics & Pharmacoproteomics
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Shouji Shimoyama”

